| Kevin Scott Cahill, MD, PHD | |
|
610 Ocean Hwy W, Supply, NC 28462-4048 | |
| (910) 356-6100 | |
| (910) 356-6100 |
| Full Name | Kevin Scott Cahill |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 19 Years |
| Location | 610 Ocean Hwy W, Supply, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811157613 | NPI | - | NPPES |
| 5920275 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 224857 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carolinas Medical Center-northeast | Concord, NC | Hospital |
| Carolinas Medical Center/behav Health | Charlotte, NC | Hospital |
| Novant Health Presbyterian Medical Center | Charlotte, NC | Hospital |
| Stanly Regional Medical Center | Albemarle, NC | Hospital |
| Carolinas Medical Center-pineville | Charlotte, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Spine Institute Pc | 1951641000 | 3 |
News Archive
Researchers at UCLA have developed a molecular compound that improves balance and coordination in mice with early stage Parkinson's disease.
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.
Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced the completion of its rights offering and private placement that together will result in gross proceeds of approximately $3.2 million to Nephros.
› Verified 9 days ago
| Entity Name | Coastal Spine Institute Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346704145 PECOS PAC ID: 1951641000 Enrollment ID: O20200615002803 |
News Archive
Researchers at UCLA have developed a molecular compound that improves balance and coordination in mice with early stage Parkinson's disease.
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.
Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced the completion of its rights offering and private placement that together will result in gross proceeds of approximately $3.2 million to Nephros.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Scott Cahill, MD, PHD 610 Ocean Hwy W, Supply, NC 28462-4048 Ph: (910) 356-6100 | Kevin Scott Cahill, MD, PHD 610 Ocean Hwy W, Supply, NC 28462-4048 Ph: (910) 356-6100 |
News Archive
Researchers at UCLA have developed a molecular compound that improves balance and coordination in mice with early stage Parkinson's disease.
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.
Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced the completion of its rights offering and private placement that together will result in gross proceeds of approximately $3.2 million to Nephros.
› Verified 9 days ago